BI Asset Management Fondsmaeglerselskab A S Buys 7,091 Shares of Zoetis Inc. $ZTS

BI Asset Management Fondsmaeglerselskab A S lifted its stake in shares of Zoetis Inc. (NYSE:ZTS) by 1.9% in the third quarter, according to the company in its most recent filing with the SEC. The fund owned 374,143 shares of the company’s stock after buying an additional 7,091 shares during the quarter. BI Asset Management Fondsmaeglerselskab A S owned about 0.08% of Zoetis worth $54,745,000 as of its most recent SEC filing.

Other institutional investors and hedge funds have also bought and sold shares of the company. Auxano Advisors LLC raised its holdings in Zoetis by 104.7% in the 3rd quarter. Auxano Advisors LLC now owns 3,249 shares of the company’s stock valued at $475,000 after acquiring an additional 1,662 shares during the period. Savant Capital LLC grew its position in shares of Zoetis by 58.4% in the third quarter. Savant Capital LLC now owns 10,716 shares of the company’s stock valued at $1,568,000 after purchasing an additional 3,952 shares during the last quarter. Machina Capital S.A.S. grew its position in shares of Zoetis by 124.2% in the third quarter. Machina Capital S.A.S. now owns 17,251 shares of the company’s stock valued at $2,524,000 after purchasing an additional 9,557 shares during the last quarter. Ashton Thomas Private Wealth LLC increased its stake in shares of Zoetis by 9.8% during the third quarter. Ashton Thomas Private Wealth LLC now owns 30,236 shares of the company’s stock worth $4,424,000 after purchasing an additional 2,692 shares during the period. Finally, Adell Harriman & Carpenter Inc. lifted its holdings in Zoetis by 59.6% during the 3rd quarter. Adell Harriman & Carpenter Inc. now owns 2,075 shares of the company’s stock worth $304,000 after purchasing an additional 775 shares during the last quarter. Institutional investors and hedge funds own 92.80% of the company’s stock.

Zoetis Stock Performance

NYSE ZTS opened at $126.69 on Thursday. The firm’s 50 day simple moving average is $124.00 and its 200 day simple moving average is $136.62. The firm has a market capitalization of $55.83 billion, a price-to-earnings ratio of 21.33, a P/E/G ratio of 2.11 and a beta of 0.96. The company has a current ratio of 3.64, a quick ratio of 2.28 and a debt-to-equity ratio of 1.31. Zoetis Inc. has a 1 year low of $115.25 and a 1 year high of $177.40.

Zoetis (NYSE:ZTS) last released its earnings results on Tuesday, November 4th. The company reported $1.70 earnings per share for the quarter, topping the consensus estimate of $1.62 by $0.08. Zoetis had a return on equity of 57.19% and a net margin of 28.21%.The firm had revenue of $2.40 billion during the quarter, compared to analysts’ expectations of $2.42 billion. During the same period in the prior year, the company earned $1.58 earnings per share. The company’s quarterly revenue was up .5% on a year-over-year basis. As a group, research analysts expect that Zoetis Inc. will post 6.07 earnings per share for the current fiscal year.

Zoetis Increases Dividend

The firm also recently disclosed a quarterly dividend, which will be paid on Tuesday, March 3rd. Investors of record on Tuesday, January 20th will be paid a $0.53 dividend. This represents a $2.12 annualized dividend and a yield of 1.7%. This is a boost from Zoetis’s previous quarterly dividend of $0.50. The ex-dividend date of this dividend is Tuesday, January 20th. Zoetis’s payout ratio is 35.69%.

Wall Street Analysts Forecast Growth

A number of research analysts have commented on the company. Bank of America lowered Zoetis from a “buy” rating to a “neutral” rating and set a $135.00 price objective on the stock. in a report on Monday, December 15th. Piper Sandler restated a “neutral” rating and issued a $135.00 price target (down from $190.00) on shares of Zoetis in a research note on Thursday, January 22nd. JPMorgan Chase & Co. lowered their price target on shares of Zoetis from $230.00 to $200.00 and set an “overweight” rating on the stock in a research report on Wednesday, November 5th. BTIG Research reissued a “buy” rating and issued a $160.00 price objective on shares of Zoetis in a report on Wednesday, December 3rd. Finally, Wall Street Zen raised shares of Zoetis from a “hold” rating to a “buy” rating in a report on Friday, January 23rd. Five equities research analysts have rated the stock with a Buy rating, seven have issued a Hold rating and one has assigned a Sell rating to the stock. According to data from MarketBeat.com, the stock currently has a consensus rating of “Hold” and a consensus target price of $152.45.

Zoetis Company Profile

Zoetis Inc (NYSE: ZTS) is a global animal health company that develops, manufactures and markets a broad portfolio of products and services for companion animals and livestock. The company’s offerings include pharmaceuticals, vaccines and biologics, parasiticides and anti-infectives, as well as diagnostic instruments, consumables and laboratory testing services. Zoetis serves the veterinary community, livestock producers and other animal-health customers with products designed to prevent, detect and treat disease and to support animal productivity and welfare.

Zoetis traces its roots to the animal health business of Pfizer and became an independent, publicly traded company following a 2013 separation and initial public offering.